Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 5;14(1):153.
doi: 10.1038/s41408-024-01118-3.

Blood neurofilament light chain measurements in adults with CNS histiocytic neoplasms

Samantha A Banks  1 , Paul Decker  2 , Eoin P Flanagan  1   3   4 , Anastasia Zekeridou  1   3   4 , Ronald S Go  5 , Jithma P Abeykoon  5 , Gaurav Goyal  6 , Jason R Young  7 , Matthew J Koster  8 , Robert Vassallo  9 , Jay H Ryu  9 , Caroline J Davidge-Pitts  10 , Aishwarya Ravindran  11 , Julio C Sartori Valinotti  12 , N Nora Bennani  5 , Mithun V Shah  5 , Karen L Rech  13 , Corrie R Bach  7 , Jeanette E Eckel-Passow  2 , W Oliver Tobin  14   15 ; Mayo Clinic-University of Alabama at Birmingham Histiocytosis Working Group and Center for Multiple Sclerosis and Autoimmune Neurology at Mayo Clinic
Affiliations

Blood neurofilament light chain measurements in adults with CNS histiocytic neoplasms

Samantha A Banks et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Dr. Banks was supported by Grant Number UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS), its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH; Dr Flanagan has served on advisory boards for Alexion, Genentech, Horizon Therapeutics and UCB. He has received research support from UCB, he has received speaker honoraria from Pharmacy Times, he received royalties from UpToDate, he is a site principal investigator in a randomized clinical trial of Rozanolixizumab for relapsing myelin oligodendrocyte glycoprotein antibody-associated disease run by UCB and is a site principal investigator and a member of the steering committee for a clinical trial of satralizumab for relapsing myelin oligodendrocyte glycoprotein antibody-associated disease run by Roche/Genentech, he has received funding from the NIH (R01NS113828), he is a member of the medical advisory board of the MOG project and is an editorial board member of Neurology, Neuroimmunology and Neuroinflammation, The Journal of the Neurological Sciences and Neuroimmunology Reports, a patent has been submitted on DACH1-IgG as a biomarker of paraneoplastic autoimmunity; Dr. Zekeridou reports patents submitted for PDE10A-IgG, DACH1-IgG and Tenascin-R-IgG as biomarkers of neurological paraneoplastic autoimmunity, research funding from Roche not related to this project and consulting for Alexion Pharmaceuticals without personal compensation; Dr. Tobin reports receiving research funding from the National institutes of Health, Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology and Mallinckrodt Inc, he receives royalties from the publication of “Mayo Clinic Cases in Neuroimmunology” (OUP); Paul Decker, Ronald Go, Jithma Abeykoon, Gaurav Goyal, Jason Young, Matthew Koster, Robert Vassallo, Jay Ryu, Caroline Davidge-Pitts, Aishwarya Ravindran, Julio Sartori Valinotti, Nora Bennani, Mithun Shah, Corrie Bach, Jeanette Eckel-Passow declare no competing interests.

Figures

Fig. 1
Fig. 1. Examples of MRI features evaluated and summary boxplots.
A, B T2 hyperintensity in bilateral middle cerebellar peduncles extending into cerebellum and pons (A, arrows) with associated gadolinium enhancement on T1 weighted images (B, arrows), defined as parenchymal brain involvement, with enhancement. C Gadolinium enhancement on T1 weighted images in subarachnoid spaces suggestive of leptomeningeal disease (C, arrow), defined in the study cohort as non-parenchymal CNS involvement, without parenchymal enhancement. D Large dural-based lesion with homogenous enhancement on T1 post-gadolinium sequences (D, arrow) with compression of brainstem and encasement of the vertebral artery, defined as non-parenchymal CNS involvement, without parenchymal enhancement. E Boxplot comparing cases to controls; neurofilament light chain (NfL) by Simoa assay transformed to Ella level plus Ella assay in patients with central nervous system (CNS) histiocytosis were significantly elevated compared to those with histiocytosis without CNS involvement (P < 0.0001). F NfL by Simoa assay transformed to Ella level plus Ella assay in patients with histiocytic disease without CNS involvement compared to those with CNS involvement with and without parenchymal involvement. NfL was significantly higher in those with parenchymal involvement than non-CNS histiocytosis (P < 0.0001). G NfL by Simoa assay transformed to Ella level plus Ella assay in patients with histiocytic disease without CNS involvement compared to those with CNS involvement with and without parenchymal enhancement. NfL was significantly higher in those with parenchymal enhancement than non-CNS histiocytosis (P < 0.0001).
See this image and copyright information in PMC

References

    1. Go RS, Jacobsen E, Baiocchi R, Buhtoiarov I, Butler EB, Campbell PK, et al. Histiocytic neoplasms, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2021;19:1277–303.10.6004/jnccn.2021.0053 - DOI - PubMed
    1. Arnaud L, Hervier B, Néel A, Hamidou MA, Kahn J-E, Wechsler B, et al. CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood J Am Soc Hematol. 2011;117:2778–82. - PubMed
    1. Nathoo N, Uhm JH, Porter AB, Hammack J, Jaeckle KA, Mrugala MM, et al. Clinical features and outcomes in primary nervous systemhistiocytic neoplasms. Blood Cancer J. 2024;14:101. 10.1038/s41408-024-01083-x - DOI - PMC - PubMed
    1. Goyal G, Heaney ML, Collin M, Cohen-Aubart F, Vaglio A, Durham BH, et al. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood. 2020;135:1929–45. 10.1182/blood.2019003507 - DOI - PubMed
    1. Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14:577–89. 10.1038/s41582-018-0058-z - DOI - PubMed

Publication types

LinkOut - more resources